Total Payments
$1,413
2024 Payments
$215.44
Companies
26
Transactions
112
Medicare Patients
5,218
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$1,413 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,413 | 112 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $281.18 | 59 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $259.40 | 8 | $0 (2024) |
| Merck Sharp & Dohme LLC | $192.89 | 4 | $0 (2023) |
| Insmed, Inc. | $98.89 | 5 | $0 (2023) |
| ABBVIE INC. | $81.81 | 3 | $0 (2024) |
| Shire North American Group Inc | $66.32 | 4 | $0 (2017) |
| GlaxoSmithKline, LLC. | $62.78 | 4 | $0 (2019) |
| Theravance Biopharma Inc. | $54.75 | 4 | $0 (2017) |
| Gilead Sciences, Inc. | $36.99 | 2 | $0 (2019) |
| Ferring Pharmaceuticals Inc. | $28.94 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $215.44 | 9 | Takeda Pharmaceuticals U.S.A., Inc. ($61.24) |
| 2023 | $171.43 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($103.39) |
| 2022 | $298.07 | 7 | Merck Sharp & Dohme LLC ($144.38) |
| 2021 | $17.71 | 1 | Insmed, Inc. ($17.71) |
| 2019 | $103.69 | 7 | GlaxoSmithKline, LLC. ($17.75) |
| 2018 | $193.19 | 36 | PFIZER INC. ($111.38) |
| 2017 | $413.90 | 46 | PFIZER INC. ($121.02) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 5 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/21/2017 | GlaxoSmithKline, LLC. | ADVAIR (Drug), FLOVENT | Food and Beverage | In-kind items and services | $10.67 | General |
| Category: RESPIRATORY | ||||||
| 04/13/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.57 | General |
| Category: Cardiovascular | ||||||
| 04/11/2017 | PFIZER INC. | FLECTOR PATCH (Drug), LYRICA, EMBEDA | Food and Beverage | In-kind items and services | $6.12 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 03/15/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), ZEPATIER | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/14/2017 | PFIZER INC. | EMBEDA (Drug), FLECTOR PATCH, LYRICA | Food and Beverage | In-kind items and services | $6.49 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 03/01/2017 | Shire North American Group Inc | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: IMMUNOLOGY | ||||||
| 02/21/2017 | PFIZER INC. | FLECTOR PATCH (Drug), EMBEDA, LYRICA | Food and Beverage | In-kind items and services | $6.12 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 02/14/2017 | PFIZER INC. | LYRICA (Drug), FLECTOR PATCH, EMBEDA | Food and Beverage | In-kind items and services | $0.65 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 02/02/2017 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $12.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/02/2017 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $11.04 | General |
| Category: Diabetes | ||||||
| 01/18/2017 | PFIZER INC. | EMBEDA (Drug), FLECTOR PATCH, LYRICA | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 01/05/2017 | Arbor Pharmaceuticals, Inc. | Evekeo (Drug) | Food and Beverage | Cash or cash equivalent | $13.72 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,360 | 9,523 | $850,004 | $349,114 |
| 2022 | 20 | 1,247 | 48,568 | $723,134 | $283,394 |
| 2021 | 18 | 1,237 | 14,991 | $720,050 | $330,423 |
| 2020 | 15 | 1,374 | 4,468 | $714,602 | $322,114 |
Total Patients
5,218
Total Services
77,550
Medicare Billing
$1.3M
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 402 | 2,445 | $366,613 | $158,000 | 43.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 52 | 4,920 | $221,400 | $89,847 | 40.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 285 | 322 | $96,600 | $46,279 | 47.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 152 | 177 | $44,250 | $18,862 | 42.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 261 | $53,766 | $16,822 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 99 | $28,908 | $9,104 | 31.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 26 | 98 | $17,052 | $4,568 | 26.8% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 21 | 79 | $7,742 | $2,115 | 27.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 63 | 99 | $3,168 | $951.45 | 30.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 62 | 118 | $1,808 | $929.04 | 51.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 32 | 59 | $1,829 | $600.30 | 32.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 36 | 58 | $1,160 | $433.77 | 37.4% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 32 | 58 | $580.00 | $290.39 | 50.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 712 | $4,984 | $241.41 | 4.8% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 12 | 18 | $144.00 | $70.92 | 49.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 361 | 2,241 | $336,150 | $140,161 | 41.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 234 | 260 | $78,000 | $45,679 | 58.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 30 | 2,361 | $97,715 | $39,578 | 40.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 132 | 151 | $37,750 | $17,547 | 46.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 230 | $46,736 | $15,183 | 32.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 89 | $25,378 | $8,582 | 33.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 30 | 97 | $16,832 | $4,561 | 27.1% |
| 96374 | Injection of drug or substance into vein | Office | 2022 | 25 | 145 | $14,221 | $4,480 | 31.5% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2022 | 11 | 41,762 | $41,762 | $1,586 | 3.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $4,394 | $1,520 | 34.6% |
About Dr. James Gordon, M.D
Dr. James Gordon, M.D is a Infectious Disease healthcare provider based in Novi, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144239559.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Gordon, M.D has received a total of $1,413 in payments from pharmaceutical and medical device companies, with $215.44 received in 2024. These payments were reported across 112 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($1,413).
As a Medicare-enrolled provider, Gordon has provided services to 5,218 Medicare beneficiaries, totaling 77,550 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Novi, MI
- Active Since 08/05/2006
- Last Updated 01/11/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1144239559
Products in Payments
- CUVITRU (Biological) $325.72
- LYRICA (Drug) $195.54
- VAXNEUVANCE (Biological) $144.38
- Arikayce (Drug) $98.89
- VIBATIV (Drug) $54.75
- TEFLARO (Drug) $54.35
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug) $53.91
- TRELEGY ELLIPTA (Drug) $36.20
- REBYOTA (Biological) $28.94
- AVYCAZ (Drug) $27.46
- Saxenda (Drug) $24.90
- LINZESS (Drug) $22.90
- DIFICID (Drug) $18.21
- ZEPATIER (Drug) $18.16
- NUZYRA (Drug) $17.11
- ELIQUIS (Drug) $16.57
- EMBEDA (Drug) $16.04
- Vabomere (Drug) $15.99
- ANORO (Drug) $15.91
- XARELTO (Drug) $15.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.